Author Contributions: Dr Demers had full access
to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
Study concept and design: McMurray, Swedberg,
Pfeffer, Granger, McKelvie, Michelson, Yusuf.
Acquisition of data: McMurray, Swedberg, Pfeffer,
McKelvie, Östergren, Wang.
Analysis and interpretation of data: Demers,
McMurray, Swedberg, Pfeffer, Olofsson, Östergren, Michelson, Johansson,
Drafting of the manuscript: Demers, McMurray,
Swedberg, Pfeffer, Yusuf.
Critical revision of the manuscript for important
intellectual content: Demers, McMurray, Swedberg, Pfeffer, Granger,
Olofsson, McKelvie, Östergren, Michelson, Johansson, Wang, Yusuf.
Statistical analysis: Olofsson, Johansson,
Obtained funding: McMurray, Swedberg, Michelson.
Administrative, technical, or material support:
McKelvie, Östergren, Michelson, Yusuf.
Study supervision: Demers, McMurray, Swedberg,
Pfeffer, Östergren, Yusuf.
Financial Disclosures: Drs Demers, McMurray,
Swedberg, Pfeffer, Granger, McKelvie, Östergren, and Yusuf have received
research grants, honoraria for lectures, and/or consulting fees from a number
of pharmaceutical companies manufacturing and marketing inhibitors of the
renin-angiotensin-aldosterone system, including AstraZeneca, Boehringer-Ingelheim,
Bristol-Myers Squibb/Sanofi-Aventis, Merck, Novartis, Pfizer, and Takeda.
Dr Wang reported no disclosures.
Funding/Support: AstraZeneca funded the CHARM
Role of the Sponsor: Representatives from AstraZeneca
were involved in protocol design; in collection, management, analysis, and
interpretation of data; and in manuscript preparation.
Independent Statistical Review: Independent
statistical review of the data included in this analysis was perfomed by Stuart
Pocock, PhD (also served on the CHARM Data Safety and Monitoring Committee)
and Duolao Wang, both of the London School of Hygiene and Tropical Medicine.